Search Result

Results for "

Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Amylin Receptor (1) Amyloid-β (1) Apoptosis (1) Complement System (1) CXCR (1) Isotope-Labeled Compounds (8) Parasite (1) PD-1/PD-L1 (1) Radionuclide-Drug Conjugates (RDCs) (1) Ser/Thr Protease (3) Somatostatin Receptor (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (2) Metabolic Disease (4) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10215

*Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2*	Parasite	Infection
Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2 (compound 40) is a potent Plasmodium subtilisin-like protease 1 (SUB1) inhibitor. SUB1-IN-1 shows IC₅₀ values of 12 nM and 10 nM against P. vivax and P. falciparum SUB1 (Pv- and PfSUB1), respectively .

HY-P4476

Suc-AAPA-pNA 1 Publications Verification	Ser/Thr Protease	Others
Suc-AAPA-pNA is a substrate for chymotrypsin A and elastase. Suc-AAPA-pNA can be used for enzyme activity assay ^[2] .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Seglitide (MK-678) is an orally active, selective *SSTR2* agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with *pA2* values of 6.50, 6.24 and 6.09 against SS₁₄, SS₂₅ and SS₂₈, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus ^[2] .

HY-P4460

AAA-pNA	Ser/Thr Protease	Cancer
AAA-pNA is a chromogenic substrate of Tripeptidyl-peptidase II. AAA-pNA can be used to test Tripeptidyl-peptidase II activity .

HY-106103A

Seglitide acetate MK 678 Acetate; L 36358 Acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes ^[2] .

HY-W014786

DL-Alanyl-DL-leucine	Amino Acid Derivatives	Others
DL-Alanyl-DL-leucine is a dipeptide compound composed of alanine and leucine .

HY-P4470

Phe-Pro-Ala-pNA	Ser/Thr Protease	Cancer
Phe-Pro-Ala-pNA is a chromogenic substrate of tripeptidyl peptidase. Phe-Pro-Ala-pNA can be used to test tripeptidyl peptidase activity .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[2] .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA	Isotope-Labeled Compounds Apoptosis	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-158994S

MEGDSRGG-(Ala-13C3,15N)-GGEA-(Leu-13C6,15N)-DPESAASSLSGAS TFA	Isotope-Labeled Compounds	Others
MEGDSRGG-(Ala- ¹³C₃, ¹⁵N)-GGEA-(Leu- ¹³C₆, ¹⁵N)-DPESAASSLSGAS TFA is a ¹³C- and ¹⁵N-labeled peptide containing ¹³C₃, ¹⁵N-labeled alanine (Ala) and ¹³C₆, ¹⁵N-labeled leucine (Leu).

HY-P0058S

Pramlintide-(Ala-13C3,15N)	Isotope-Labeled Compounds Amylin Receptor	Metabolic Disease Cancer
Pramlintide-(Ala- ¹³C₃, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P6696S

β-CL, Ala(13C3,15N) TFA	Isotope-Labeled Compounds	Others
β-CL, Ala(sup>13C₃, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled β-CL TFA.

HY-173103S

FYDPL(Ala-13C3,15N)GK TFA	Isotope-Labeled Compounds	Others
FYDPL(Ala- ¹³C₃, ¹⁵N)GK TFA is the ¹³C- and ¹⁵N-labeled FYDPL(Ala)GK TFA.

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name	Target	Research Area

HY-P10215

*Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2*	Parasite	Infection
Ac-{Cpg}-Thr-Ala-{Ala(CO)}-Asp-{Cpg}-NH2 (compound 40) is a potent Plasmodium subtilisin-like protease 1 (SUB1) inhibitor. SUB1-IN-1 shows IC₅₀ values of 12 nM and 10 nM against P. vivax and P. falciparum SUB1 (Pv- and PfSUB1), respectively .

HY-P4476

Suc-AAPA-pNA 1 Publications Verification	Ser/Thr Protease	Others
Suc-AAPA-pNA is a substrate for chymotrypsin A and elastase. Suc-AAPA-pNA can be used for enzyme activity assay ^[2] .

HY-P3440

WL12	Radionuclide-Drug Conjugates (RDCs) PD-1/PD-L1	Cancer
WL12 is a specifically targeting programmed death ligand 1 (PD-L1) binding peptide. WL12 can be radiolabeled by different radionuclides, generating radiotracers, which can assess the tumor PD-L1 expression .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Seglitide (MK-678) is an orally active, selective *SSTR2* agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with *pA2* values of 6.50, 6.24 and 6.09 against SS₁₄, SS₂₅ and SS₂₈, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus ^[2] .

HY-P4460

AAA-pNA	Ser/Thr Protease	Cancer
AAA-pNA is a chromogenic substrate of Tripeptidyl-peptidase II. AAA-pNA can be used to test Tripeptidyl-peptidase II activity .

HY-106103A

Seglitide acetate MK 678 Acetate; L 36358 Acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes ^[2] .

HY-W014786

DL-Alanyl-DL-leucine	Amino Acid Derivatives	Others
DL-Alanyl-DL-leucine is a dipeptide compound composed of alanine and leucine .

HY-P4470

Phe-Pro-Ala-pNA	Ser/Thr Protease	Cancer
Phe-Pro-Ala-pNA is a chromogenic substrate of tripeptidyl peptidase. Phe-Pro-Ala-pNA can be used to test tripeptidyl peptidase activity .

HY-125357

Ternatin	Peptides	Metabolic Disease
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC₅₀ of 0.027 μM in 3T3-L1 adipocytes .

HY-P5218

Acetyl dipeptide-3 aminohexanoate	Peptides	Others
Acetyl dipeptide-3 aminohexanoate is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA	Isotope-Labeled Compounds Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[2] .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)	Isotope-Labeled Compounds	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA	Isotope-Labeled Compounds Apoptosis	Others
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-158994S

MEGDSRGG-(Ala-13C3,15N)-GGEA-(Leu-13C6,15N)-DPESAASSLSGAS TFA	Isotope-Labeled Compounds	Others
MEGDSRGG-(Ala- ¹³C₃, ¹⁵N)-GGEA-(Leu- ¹³C₆, ¹⁵N)-DPESAASSLSGAS TFA is a ¹³C- and ¹⁵N-labeled peptide containing ¹³C₃, ¹⁵N-labeled alanine (Ala) and ¹³C₆, ¹⁵N-labeled leucine (Leu).

HY-P0058S

Pramlintide-(Ala-13C3,15N)	Isotope-Labeled Compounds Amylin Receptor	Metabolic Disease Cancer
Pramlintide-(Ala- ¹³C₃, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P6696S

β-CL, Ala(13C3,15N) TFA	Isotope-Labeled Compounds	Others
β-CL, Ala(sup>13C₃, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled β-CL TFA.

HY-P3252AS

Pegcetacoplan-13C3,15N TFA	Isotope-Labeled Compounds Complement System	Inflammation/Immunology
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Cat. No.	Product Name	Chemical Structure

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA
β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[2] .

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death ^[2] .

HY-P1142S

GLP-2(rat) (Ala-13C3,15N)
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-P1142S1

GLP-2(rat) (Ala-13C3,15N) TFA
GLP-2(rat) (Ala- ¹³C3, ¹⁵N) TFA is ¹³C and ¹⁵N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).

HY-158994S

MEGDSRGG-(Ala-13C3,15N)-GGEA-(Leu-13C6,15N)-DPESAASSLSGAS TFA
MEGDSRGG-(Ala- ¹³C₃, ¹⁵N)-GGEA-(Leu- ¹³C₆, ¹⁵N)-DPESAASSLSGAS TFA is a ¹³C- and ¹⁵N-labeled peptide containing ¹³C₃, ¹⁵N-labeled alanine (Ala) and ¹³C₆, ¹⁵N-labeled leucine (Leu).

HY-P0058S

Pramlintide-(Ala-13C3,15N)
Pramlintide-(Ala- ¹³C₃, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Pramlintide. Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .

HY-P6696S

β-CL, Ala(13C3,15N) TFA
β-CL, Ala(sup>13C₃, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled β-CL TFA.

HY-173103S

FYDPL(Ala-13C3,15N)GK TFA
FYDPL(Ala- ¹³C₃, ¹⁵N)GK TFA is the ¹³C- and ¹⁵N-labeled FYDPL(Ala)GK TFA.

HY-P3252AS

Pegcetacoplan-13C3,15N TFA
Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Pegcetacoplan-13C3,15N TFA

Pegcetacoplan- ¹³C₃, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: